The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer | Zendy

James E. M. Watson | Zendy; Jonathan Stewart | Zendy; Gérard I. Evan | Zendy; Anne Ritson | Zendy; Karol Sikora | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer

Author(s) -

James E. M. Watson,

Jonathan Stewart,

Gérard I. Evan,

Anne Ritson,

Karol Sikora

Publication year - 1986

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1986.56

Subject(s) - monoclonal antibody , testicular cancer , flow cytometry , biology , teratoma , cancer research , cancer , pathology , antibody , microbiology and biotechnology , immunology , medicine , genetics

A sensitive flow cytometric assay has been developed using a monoclonal antibody, Myc 1-6E10, to quantitate c-myc oncoprotein levels in nuclei isolated from wax embedded testicular tumours. The oncoprotein (p62c-myc) level increased significantly with increasing teratoma differentiation. Patients with intermediate and undifferentiated tumours who developed recurrence had lower p62c-myc levels than those who were disease free since their initial treatment. Such quantitative biochemical methods may provide new prognostic indices for cancer patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research